A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, FIXED-DOSE STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF NBI-98854 FOR THE TREATMENT OF TARDIVE DYSKINESIA

Registry ID

NBI-98854-1304

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

NEUROCRINE BIOSCIENCES INC

Start date

2015-04-08

Completion date

2016-08-03

Last update

2014-12-18

Conditions

• TARDIVE DYSKINESIA

View on source registry